Table 5.

Univariate and Multivariate Factors Associated with Disease-Free Survival

Factors	Event/total	Univariate		Multivariate
		Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	p
Stage
1	6/38	1		1
2	44/246	0.95 (0.40–2.23)	0.901	0.88 (0.37–2.10)	0.773
3	40/127	1.93 (0.82–4.57)	0.133	1.69 (0.69–4.13)	0.248
Breast cancer subset
Luminal	57/269	1		1
Luminal HER2	13/51	1.26 (0.69–2.30)	0.453	1.02 (0.55–1.90)	0.948
Triple-negative	10/50	0.99 (0.50–1.93)	0.966	0.95 (0.46–1.94)	0.881
ER−/HER2+	10/41	1.26 (0.65–2.48)	0.494	1.14 (0.57–2.27)	0.715
Grade
1	4/38	1		1
2	51/229	2.78 (0.82–6.30)	0.113	2.01 (0.71–5.70)	0.191
3	25/117	2.28 (0.79–6.60)	0.125	1.97 (0.65–5.95)	0.228
Unavailable	10/27	4.34 (1.36–13.84)	0.013	3.75 (1.13–12.45)	0.031
LVI
Negative	33/181	1		1
Positive	27/95	1.58 (0.95–2.63)	0.078	1.19 (0.69–2.05)	0.525
NA	30/135	1.21 (0.74–1.99)	0.448	1.13 (0.68–1.86)	0.647
Follow-up type
Standard	53/213	1.47 (0.97–2.24)	0.072	0.80 (0.30–2.13)	0.655
Alternative	37/198	1		1
Surveillance CXR
Yes	31/166	0.69 (0.45–1.07)	0.099	0.66 (0.28–1.59)	0.357
No	59/245	1		1
Surveillance LFT
Yes	17/124	0.50 (0.29–0.84)	0.01	0.48 (0.24–0.96)	0.037
No	73/287	1		1

CI, confidence interval; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; NA, not available; LVI, lympho-vascular invasion; CXR, chest X-ray; LFT, liver function test